MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Intellia Therapeutics
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1200
- sponsor
- Intellia Therapeutics
- conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- interventions
- BIOLOGICAL: NTLA-2001; DRUG: Placebo
- start date
- 2023-12-13
- start date type
- ACTUAL
- primary completion date
- 2027-12-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT06128629
- Published
- Nov 13, 2023
- Updated
- Mar 27, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT06128629
- Categories
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials